VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISAL 2019 | Risk-adapted therapy of AML

Christoph Röllig, MD, MSc, of Dresden University of Technology, Dresden, Germany, discusses the risk-adapted therapy of acute myeloid leukemia (AML), highlighting the rationale behind combination therapy in specific subgroups. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter